Lipoprotein Particle Profile
Lipoprotein Particle Profile
Overview of lipoprotein particles and cholesterol Cholesterol testing has historically been used as the standard indicator for cardiovascular disease classified as HDL (good) or LDL (bad). However, it is actually the lipoprotein particles that carry the cholesterol throughout the body, not necessarily the cholesterol within them, that are responsible for key steps in plaque production and the resulting development of cardiovascular disease. Approximately 50 percent of people suffering from heart attacks have shown “normal” cholesterol numbers (NIH – National Heart Blood and Lung Institute). Now there is an advanced cholesterol testing technology which accurately measures both the density and number of lipoprotein particles. This test is the Lipoprotein Particle Profile™, or LPP™, from SpectraCell Laboratories. Measuring the lipoprotein subgroups is the only way to evaluate new risk factors, which is crucial for an accurate assessment of cardiovascular risk – according to the National Cholesterol Education Program (NCEP). NCEP new Risk Factors:
- Small, dense LDL: these atherogenic particles are easily oxidized and penetrate the arterial endothelium to form plaqu
- Lp(a): this small, dense LDL is involved in thrombosis RLP (Remnant Lipoprotein): is very atherogenic, has a similar composition and density of plaque, is believed to be a building block of plaque and does not need to be oxidized like other LDL particle
- HDL2b: positively correlates with heart health because it is an indicator of how well excess lipids are removed
Lipoprotein Particle Profile™ (LPP™) Providing a Complete Look at Lipoprotein Subgroups SpectraCell’s LPP™ test is a proprietary technology originally developed at Texas A&M University that separates the lipoproteins in blood serum by density using analytical ultracentrifugation, the CDC gold standard for lipoprotein testing, then measures the particles photometrically.
Use LPP™ in your practice for accurate atherogenic risk assessments Traditionally, the standard lipid panel calculates LDL from measurements of the other lipoproteins. In contrast, the LPP™ method presents values for all of the lipoproteins from direct measurement. SpectraCell’s LPP™ technology aids the physician in assessing a patient’s cardiovascular risk. With LPP™, a physician can begin to treat patients with atherogenic lipoprotein profiles before overt dyslipidemia becomes apparent.
References & Resources
- Chandra R, Macfarlane R. Remnant Lipoprotein Density Profiling by CsBiEDTA Density Gradient Ultracentrifugation. Analytical Chemistry. 2006;78:680-685
- Espinosa L, Macfarlane R, McNeal C. Method for Lipoprotein(a) Density Profiling by BiEDTA Differential Density Lipoprotein Ultracentrifugation. Analytical Chemistry. 2006; 78:438-444
- Nakajima K, Nakano T, Tanaka A. The oxidative modification hypothesis of atherosclerosis: the comparison of atherogenic effects on oxidized LDL and remant lipoproteins in plasma. Clin Chim Acta. 2006;367(1-2):36-47. Packard CJ. Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease. Curr Opin Lipidol. 2006;17(4):412-7
- Watanabe H, et al. Decreased high-density lipoprotein (HDL) particle size, prebeta-, and large HDL subspecies concentration in Finnish low-HDL families: relationships with intima-media thickness. Aterioscler Thromb Vasc Biol. 2006;26(4):897-902
- Bell N, Johnson J, Donahoe E, Macfarlane R. Metal Ion Complexes of EDTA as Solutes for Density Gradient Ultracentrifugation: Influence of Metal Ions. Analytical Chemistry. 2005;77:8165-8172
- Capuzzi D, Carey C, Lincoff A, Morgan J. High-density Lipoprotein Subfractions and Risk of Coronary Artery Disease. Current Atherosclerosis Reports. 2004;6:359-365
- Marcovina SM, Koschinsky ML. Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside. Curr Opin Lipidol. 2003;14(4):361-6
- Otvos J. Why Cholesterol Measurements May be Misleading about Lipoprotein Levels and Cardiovascular Disease Risk – Clinical Implications of Lipoprotein Quantification Using NMR Spectroscopy. J Lab Med. 2002;26(11/12):544-550
- Cupples A, McNamara J, Nakajima K, Ordovas J, Schaefer E, Shah P, Wilson P. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis. 2001;154(1):229-236
- Handbook of Lipoprotein Testing, 2nd Edition, American Association for Clinical Chemistry, Inc., Washington DC, 2000
- Masuoka H, et al. Association of Remnant-Like Particle Cholesterol with Coronary Artery Disease in Patients with Normal Total Cholesterol Levels. Am Heart J. 2000;139(2):305-310
- Seman L, et al. Lipoprotein(a)-cholesterol and coronary heart disease in the Framingham Heart Study. Clinical Chemistry. 1999;45:1039-1046
- Cantin B, Dagenais G, Després J, Lamarche B, Moorjani S, Lupien P. Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol. 1997;17(6):1098-1105
- Fortmann S, Gardner C, Krauss R. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 1996; 276(11); pages 875-881
- Dahlen G. Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis. 1994;108:111-126.